Chemotherapy-induced cardiotoxicity and mitigation
Chemotherapy-induced cardiotoxicity and mitigation is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 14k research works in it since 1956. 21.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.
- Anthracyclines
- Doxorubicin
- Cardiomyopathy
- Chemotherapy
- Cardiovascular Complications
- Trastuzumab
- Oxidative Stress
- Cardiac Dysfunction
- Prevention
- Survivors
- Research works
- 14k fractional, since 1956
- In the world top 10%
- 2.9k per year above
- Top-10% rate
- 21.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +60% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Chemotherapy-induced cardiotoxicity and mitigation research?
By volume, the United States and China publish the most (883 and 583 works in 2022–2025).
By volume, 2022–2025
- 1 United States 883 works
- 2 China 583 works
- 3 Italy 169 works
- 4 Japan 167 works
- 5 United Kingdom 116 works
- 6 India 104 works
- 7 Canada 90 works
- 8 Russia 88 works
- 9 Brazil 87 works
- 10 Türkiye 84 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Chemotherapy-induced cardiotoxicity and mitigation research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Chemotherapy-induced cardiotoxicity and mitigation research, followed by Mayo Clinic in Arizona and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 21 works
- 2 Mayo Clinic in ArizonaUnited States 15 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 14 works
- 4 Chiang Mai UniversityThailand 13 works
- 5 Sechenov UniversityRussia 12 works
- 6 Virginia Commonwealth UniversityUnited States 12 works
- 7 Harvard UniversityUnited States 11 works
- 8 Memorial Sloan Kettering Cancer CenterUnited States 11 works
- 9 Washington University in St. LouisUnited States 11 works
- 10 University of PennsylvaniaUnited States 11 works
Who are the leading researchers in Chemotherapy-induced cardiotoxicity and mitigation?
The most-cited researchers publishing on Chemotherapy-induced cardiotoxicity and mitigation include Salim Yusuf, Patrizio Lancellotti and Kunio Yagi.
- 1 Salim Yusuf Canada 4.3k citations
- 2 Patrizio Lancellotti Belgium 4.1k citations
- 3 Kunio Yagi Japan 4k citations
- 4 Ralph B. D’Agostino United States 3.8k citations
- 5 Patrick W. Serruys Netherlands 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Chemotherapy-induced cardiotoxicity and mitigation research done?
The largest centres of Chemotherapy-induced cardiotoxicity and mitigation research in 2022–2025 are Beijing (China), Shanghai (China), Moscow (Russia) and Guangzhou (China).
Largest cities, 2022–2025
Where is the best place to study Chemotherapy-induced cardiotoxicity and mitigation?
Among universities, judged by research, Chiang Mai University, Chinese Academy of Medical Sciences & Peking Union Medical College and Medical College of Wisconsin score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chiang Mai UniversityThailand | 68.6 | 29.3% | 12.4× | 13 | — |
| 2 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 52.7 | 36.2% | 4.2× | 14 | +77.2% |
| 3 | Medical College of WisconsinUnited States | 50.2 | 20.4% | 9.5× | 8 | +162.7% |
| 4 | Virginia Commonwealth UniversityUnited States | 49.4 | 12.6% | 10.6× | 12 | +129.9% |
| 5 | University of PennsylvaniaUnited States | 48.6 | 33.5% | 3.4× | 11 | +129.3% |
| 6 | Sechenov UniversityRussia | 45.6 | 9.8% | 11.1× | 12 | — |
| 7 | Harvard UniversityUnited States | 38.4 | 29.1% | 2.6× | 11 | +19.8% |
| 8 | Washington University in St. LouisUnited States | 36.7 | 13.2% | 4.6× | 11 | +245.6% |
| 9 | Mansoura UniversityEgypt | 35.1 | 24.9% | 5.1× | 8 | +30.7% |
| 10 | Ain Shams UniversityEgypt | 33.2 | 16.8% | 3.7× | 9 | +201.7% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Chemotherapy-induced cardiotoxicity and mitigation research growing?
Output in 2018–2022 was 60% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Chemotherapy-induced cardiotoxicity and mitigation.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.